Ameritas Investment Partners’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Ameritas Investment Partners’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-395	Closed	-$1K	–	3164
2019 Q1	$1K	Hold	395	–	–	﹤0.01%	2972
2018 Q4	$2K	Hold	395	–	–	﹤0.01%	2971
2018 Q3	$8K	Hold	395	–	–	﹤0.01%	2905
2018 Q2	$13K	Buy	395 +241	+156%	+$8.68K	﹤0.01%	2763
2018 Q1	$6K	Hold	154	–	–	﹤0.01%	2847
2017 Q4	$12K	Buy	+154	New	+$11.4K	﹤0.01%	2701

Other funds holding MLNT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Ameritas Investment Partners's MLNT Position: Q2 2019 in Review

Ameritas Investment Partners sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q2 2019, closing a stake of 395 shares — an estimated $1K sold.

Ameritas Investment Partners first reported a position in MLNT in Q4 2017 and held it in 6 quarters. The position peaked at $13K in Q2 2018. 53 funds tracked by Wall St. Rank hold MLNT as of Q2 2019.

Ameritas Investment Partners reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
Ameritas Investment Partners sold 395 Melinta Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $1K.
Ameritas Investment Partners first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 6 quarters.
Ameritas Investment Partners's Melinta Therapeutics, Inc. Common Stock position peaked at $13K in Q2 2018.
53 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Ameritas Investment Partners's 13F filing for Q2 2019, filed 14 Aug 2019.